Olga Viktorovna Lapina

USPTO Granted Patents = 14 (Patent Applications = 4)

CIPO Patents = 3 (Patent Applications = 1)

EPO Patents = 6 (Patent Applications = 7)

Average Co-Inventor Count = 5.3

ph-index = 3

Forward Citations = 27(Granted Patents)

Company Filing History:

10 out of 919

Gilead Sciences, Inc.

patents

4 out of 79

Gilead Pharmasset LLC

patents

Years Active: 2016-2024

Loading Chart...

14 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12162896 - Salts and polymorphs of certain MCL-1 inhibitors (2024-12-10),

2. 12102625 - Solid forms of FXR agonists (2024-10-01),

3. 11524005 - Solid forms of FXR agonists (2022-12-13),

4. 11203599 - Solid forms of an antiviral compound (2021-12-21),

5. 10946004 - Solid forms of an ASK1 inhibitor (2021-03-16),

6. 10851125 - Crystalline forms of ethyl ((S)-((((2R,5R)-5-(6-amino-9H-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl)oxy)methyl)(phenoxy)phosphoryl(-L-alaninate (2020-12-01),

7. 10604530 - Solid forms of an antiviral compound (2020-03-31),

8. 9884873 - Solid forms of an antiviral compound (2018-02-06),

9. 9862728 - Crystalline forms of an antiviral compound (2018-01-09),

10. 9643956 - Solid forms of an ASK1 inhibitor (2017-05-09),

11. 9630972 - Solid forms of an antiviral compound (2017-04-25),

12. 9562058 - Crystalline forms of an antiviral compound (2017-02-07),

13. 9487546 - Solid forms of tenofovir (2016-11-08),

14. 9273038 - Solid forms of an ion channel modulator (2016-03-01),

Olga V. Lapina: Innovator in Pharmaceutical Formulations

Introduction

Olga V. Lapina, located in Newark, CA, is a prominent inventor recognized for his contributions to the field of pharmaceuticals. With a total of 2 patents, he has significantly advanced the development of novel pharmaceutical compositions that play a crucial role in treating various medical conditions.

Latest Patents

Olga's latest patents include innovative formulations that enhance the efficacy of specific drug compounds. His first patent, titled "Salts and polymorphs of certain MCL-1 inhibitors," focuses on the salts and crystalline forms of various spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene] derivatives. This patent delves into pharmaceutical formulations and therapeutic uses, as well as methods for preparing these compounds.

The second patent, "Solid forms of FXR agonists," presents novel solid forms of FXR agonists. This patent also encompasses pharmaceutical compositions featuring these solid forms and their applications in treating conditions mediated by FXR, including methods to obtain these innovative solid forms.

Career Highlights

Olga V. Lapina has been a key innovator at Gilead Sciences, Inc., where he has utilized his expertise to develop cutting-edge pharmaceutical solutions. His commitment to advancing medical science is underscored by his impressive patent portfolio, demonstrating his continuous engagement in groundbreaking research and development.

Collaborations

Throughout his career, Olga has collaborated with notable colleagues, including Derek M. Dalton and Peter C. Fung. Their joint efforts have facilitated the progression of significant projects within the pharmaceutical sector, combining their diverse expertise to create impactful innovations.

Conclusion

As an inventor, Olga V. Lapina has made remarkable strides in the pharmaceutical industry through his patents and collaborative work. His contributions not only enhance drug formulations but also reflect a commitment to improving therapeutic outcomes for patients. With his ongoing efforts at Gilead Sciences, Inc., Olga continues to be an influential figure in the field of pharmaceutical innovations.

This text is generated by artificial intelligence and may not be accurate.